Industry Events
Immune modulation could explain how experimental Alzheimer's therapy works
Time：2013-07-09 14:13:57 Source：3G Biotech Readers：
Researchers at the University of Kentucky Sanders-Brown Center on Aging are investigating the mechanism of action behind a kind of experimental Alzheimer's therapy called intravenous immunoglobulin, also known as Gammagard™ IVIg. The therapy is being tested on a small scale for the treatment of Alzheimer's, but scientists don't yet understand how the therapy's mechanism of action works. In an animal study, researchers found that IVIg lowers amyloid deposits in the brains of mice over the course of 7 days, thereby modulating inflammation--a key event believed to be connected to clearing of amyloid deposits. The findings suggest that IVIg acts as an immune modulator, and this immune modulation helps reduce amyloid pathology
Prev : [ EU decision a rare positive for Dendreon ]
